Literature DB >> 23982879

Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis.

Dong-Tao Shi1, Mei Han, Nan Gao, Wenyan Tian, Weichang Chen.   

Abstract

Ras-association domain family 1A (RASSF1A), a candidate tumor suppressor gene, is frequently silenced and inactivated by hypermethylation of its promoter region in several human tumors. However, the association between RASSF1A promoter methylation and gastric cancer risk remains conflicting. The aim of this study was to assess the association of RASSF1A promoter methylation with gastric cancer risk by a comprehensive meta-analysis. Relevant studies were identified by searches of PubMed and Web of Science databases with no restrictions. Combined odds ratio (OR) and 95 % confidence interval (CI) were used to assess the strength of the association between RASSF1A promoter methylation and gastric cancer risk. A chi-square-based Q test and sensitivity analyses were performed to test the between-study heterogeneity and the contributions of single studies to the final results, respectively. Funnel plots were carried out to evaluate publication bias. Overall, a significant association was observed between RASSF1A promoter methylation and gastric cancer risk (OR, 12.67; 95 % CI, 8.12-19.78; p < 0.001) with no between-study heterogeneity. Subgroup analyses further revealed that gastric cancer risk was increased for individuals carrying the methylated RASSF1A compared with those with unmethylated RASSF1A. In addition, no publication bias was detected in the overall and subgroup analyses. This study identified a strong association between RASSF1A promoter methylation and risk of gastric cancer and highlighted a promising potential for RASSF1A promoter methylation in gastric cancer risk prediction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23982879     DOI: 10.1007/s13277-013-1123-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

Review 1.  DNA methylation and gene silencing in cancer.

Authors:  Stephen B Baylin
Journal:  Nat Clin Pract Oncol       Date:  2005-12

Review 2.  Genetic and epigenetic changes in stomach cancer.

Authors:  H Yokozaki; W Yasui; E Tahara
Journal:  Int Rev Cytol       Date:  2001

Review 3.  The tumor suppressor RASSF1A in human carcinogenesis: an update.

Authors:  R Dammann; U Schagdarsurengin; C Seidel; M Strunnikova; M Rastetter; K Baier; G P Pfeifer
Journal:  Histol Histopathol       Date:  2005-04       Impact factor: 2.303

Review 4.  Methylation of the RASSF1A gene in human cancers.

Authors:  Gerd P Pfeifer; Jung-Hoon Yoon; Limin Liu; Stella Tommasi; Sharon P Wilczynski; Reinhard Dammann
Journal:  Biol Chem       Date:  2002-06       Impact factor: 3.915

5.  Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.

Authors:  Xiao-Ping Zou; Bin Zhang; Xiao-Qi Zhang; Min Chen; Jun Cao; Wen-Jia Liu
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

Review 6.  The epidemiology of gastric cancer.

Authors:  David M Roder
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

7.  Profile of aberrant CpG island methylation along multistep gastric carcinogenesis.

Authors:  Gyeong Hoon Kang; Sun Lee; Jung-Sun Kim; Hwoon-Yong Jung
Journal:  Lab Invest       Date:  2003-04       Impact factor: 5.662

8.  Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.

Authors:  Yu-Cai Wang; Zheng-Hong Yu; Chang Liu; Li-Zhi Xu; Wen Yu; Jia Lu; Ren-Min Zhu; Guo-Li Li; Xin-Yi Xia; Xiao-Wei Wei; Hong-Zan Ji; Heng Lu; Yong Gao; Wei-Min Gao; Long-Bang Chen
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

9.  Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST).

Authors:  Karen Balassiano; Sheila Lima; Mazda Jenab; Kim Overvad; Anne Tjonneland; Marie Christine Boutron-Ruault; Françoise Clavel-Chapelon; Federico Canzian; Rudolf Kaaks; Heiner Boeing; Karina Meidtner; Antonia Trichopoulou; Pagona Laglou; Paolo Vineis; Salvatore Panico; Domenico Palli; Sara Grioni; Rosario Tumino; Eiliv Lund; H Bas Bueno-de-Mesquita; Mattjis E Numans; Petra H M Peeters; J Ramon Quirós; María-José Sánchez; Carmen Navarro; Eva Ardanaz; Miren Dorronsoro; Göran Hallmans; Roger Stenling; Roy Ehrnström; Sara Regner; Naomi E Allen; Ruth C Travis; Kay-Tee Khaw; G Johan A Offerhaus; Nuria Sala; Elio Riboli; Pierre Hainaut; Jean-Yves Scoazec; Bakary S Sylla; Carlos A Gonzalez; Zdenko Herceg
Journal:  Cancer Lett       Date:  2011-07-14       Impact factor: 8.679

Review 10.  The role of RASSF1A methylation in cancer.

Authors:  Luke B Hesson; Wendy N Cooper; Farida Latif
Journal:  Dis Markers       Date:  2007       Impact factor: 3.434

View more
  8 in total

1.  The FENDRR/miR-214-3P/TET2 axis affects cell malignant activity via RASSF1A methylation in gastric cancer.

Authors:  Zhaocai He; Xin Wang; Changhao Huang; Yu Gao; Chen Yang; Pengwei Zeng; Zihua Chen
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

2.  RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.

Authors:  Feiyan Shou; Feng Xu; Gang Li; Zhenhua Zhao; Ying Mao; Fangfang Yang; Hongming Wang; Hangyuan Guo
Journal:  Onco Targets Ther       Date:  2017-01-09       Impact factor: 4.147

3.  Aerobic exercise and DNA methylation in postmenopausal women: An ancillary analysis of the Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial.

Authors:  Devon J Boyne; Will D King; Darren R Brenner; John B McIntyre; Kerry S Courneya; Christine M Friedenreich
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

Review 4.  Clinical utility of RASSF1A methylation in human malignancies.

Authors:  A M Grawenda; E O'Neill
Journal:  Br J Cancer       Date:  2015-07-09       Impact factor: 7.640

5.  Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers.

Authors:  Yenkai Lim; Yunxia Wan; Dimitrios Vagenas; Dmitry A Ovchinnikov; Chris F L Perry; Melissa J Davis; Chamindie Punyadeera
Journal:  BMC Cancer       Date:  2016-09-23       Impact factor: 4.430

6.  Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer.

Authors:  Charinya Pimson; Tipaya Ekalaksananan; Chamsai Pientong; Supannee Promthet; Nuntiput Putthanachote; Krittika Suwanrungruang; Surapon Wiangnon
Journal:  PeerJ       Date:  2016-06-09       Impact factor: 2.984

7.  Promoter methylation of tumor-related genes as a potential biomarker using blood samples for gastric cancer detection.

Authors:  Jinfeng Wen; Tuo Zheng; Kefeng Hu; Chunxia Zhu; Lihua Guo; Guoliang Ye
Journal:  Oncotarget       Date:  2017-09-08

Review 8.  Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part II: A Cancer Risk Meta-Analysis.

Authors:  Óscar Rapado-González; Cristina Martínez-Reglero; Ángel Salgado-Barreira; María Arminda Santos; Rafael López-López; Ángel Díaz-Lagares; María Mercedes Suárez-Cunqueiro
Journal:  J Pers Med       Date:  2021-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.